Shivalik Rasayan Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
SHIVALIK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shivalik Rasayan's board approved unaudited standalone and consolidated results for Q3 FY26 and the nine months ended December 31, 2025. On a standalone basis, Q3 revenue fell to Rs 3,512.90 lakhs from Rs 4,016.39 lakhs a year ago (down about 12.5%), and net profit dropped sharply to Rs 203.49 lakhs from Rs 401.59 lakhs (down about 49%). For the 9-month period, standalone revenue grew to Rs 12,806.44 lakhs from Rs 10,944.43 lakhs (up around 17%), but net profit still declined to Rs 544.63 lakhs from Rs 1,054 lakhs. On a consolidated basis, 9M revenue rose to Rs 26,518.75 lakhs, while net profit attributable to controlling interest fell to Rs 761.06 lakhs from Rs 1,255.70 lakhs. The auditor (Rahul Chaudhary & Associates) issued a clean limited review report with no qualifications. The results include contribution from associate Medicamen Biotech Limited.
Despite decent top-line growth for the nine-month period, sharply lower profits and falling Q3 revenue signal significant margin pressure, which is likely to be viewed negatively by investors in the short term. Cost growth (especially depreciation, employee, and other expenses) is outpacing revenue, and the steep YoY drop in Q3 profit could weigh on the stock sentiment.